دورية أكاديمية
Podcast on Emerging Treatment Options for Pediatric Patients with ALK-Positive Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumors.
| العنوان: | Podcast on Emerging Treatment Options for Pediatric Patients with ALK-Positive Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumors. |
|---|---|
| المؤلفون: | Lowe E; Children's Hospital of The King's Daughters, Norfolk, VA, USA., Mossé YP; Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. mosse@chop.edu. |
| المصدر: | Oncology and therapy [Oncol Ther] 2024 Jun; Vol. 12 (2), pp. 247-255. Date of Electronic Publication: 2024 Apr 27. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Adis Country of Publication: New Zealand NLM ID: 101677510 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2366-1089 (Electronic) Linking ISSN: 23661089 NLM ISO Abbreviation: Oncol Ther Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Publication: 2016- : [Auckland, New Zealand] : Adis Original Publication: Cham, Switzerland : Springer International Publishing AG, [2016]- |
| مستخلص: | Anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT) are rare cancers observed predominantly in children and young adults. ALCL accounts for 10-15% of all pediatric non-Hodgkin lymphomas and is commonly diagnosed at an advanced stage of disease. In children, 84-91% of cases of ALCL harbor an anaplastic lymphoma kinase (ALK) gene translocation. IMT is a rare mesenchymal neoplasm that also tends to occur in children and adolescents. Approximately 50-70% of IMT cases involve rearrangements in the ALK gene. A combination of chemotherapeutic drugs is typically used for children with ALK-positive ALCL, and the only known curative therapy for ALK-positive IMT is complete surgical resection. Crizotinib, a first-generation ALK inhibitor, was approved in the USA in 2021 for pediatric patients and young adults with relapsed or refractory ALK-positive ALCL; however, its safety and efficacy have not been established in older adults. In 2022, crizotinib was approved for adult and pediatric patients with unresectable, recurrent, or refractory ALK-positive IMT. This podcast provides an overview of ALK-positive ALCL and IMT. We discuss the current treatment landscape, the role of ALK tyrosine kinase inhibitors, and areas of future research. (© 2024. The Author(s).) |
| References: | N Engl J Med. 2016 Jan 7;374(1):95-6. (PMID: 26736010) Pediatr Hematol Oncol. 2013 Sep;30(6):509-19. (PMID: 23758281) J Clin Oncol. 2009 Oct 20;27(30):5056-61. (PMID: 19738127) Cancer Discov. 2014 Aug;4(8):889-95. (PMID: 24875859) Blood. 2021 Jul 1;137(26):3581-3582. (PMID: 34196680) Br J Haematol. 2005 Oct;131(1):39-49. (PMID: 16173961) Haematologica. 2009 Jul;94(7):897-900. (PMID: 19570751) Arch Pathol Lab Med. 2011 Jan;135(1):19-43. (PMID: 21204709) Cancers (Basel). 2018 Mar 30;10(4):. (PMID: 29601554) Fac Rev. 2023 Aug 25;12:21. (PMID: 37655119) J Clin Oncol. 2022 Nov 1;40(31):3593-3602. (PMID: 35605188) Blood. 2021 Jul 1;137(26):3595-3603. (PMID: 33684925) Turk Patoloji Derg. 2020;36(2):173-177. (PMID: 30632123) Front Pediatr. 2021 Jul 08;9:543078. (PMID: 34307241) Lancet Oncol. 2021 Dec;22(12):1764-1776. (PMID: 34780709) J Clin Oncol. 2009 Feb 20;27(6):897-903. (PMID: 19139435) Lancet Haematol. 2023 Mar;10(3):e213-e224. (PMID: 36858678) Clin Case Rep. 2019 Nov 15;7(12):2500-2504. (PMID: 31893088) Eur J Cancer. 2021 Nov;157:198-213. (PMID: 34536944) Front Oncol. 2022 Feb 14;12:761558. (PMID: 35237506) Best Pract Res Clin Haematol. 2023 Mar;36(1):101444. (PMID: 36907641) N Engl J Med. 2010 Oct 28;363(18):1727-33. (PMID: 20979472) Pathology. 2020 Jan;52(1):100-110. (PMID: 31706671) Cancers (Basel). 2022 Jul 27;14(15):. (PMID: 35954326) J Clin Oncol. 2017 Oct 1;35(28):3215-3221. (PMID: 28787259) Am J Surg Pathol. 2007 Apr;31(4):509-20. (PMID: 17414097) Lancet Respir Med. 2023 Apr;11(4):354-366. (PMID: 36535300) Am J Surg Pathol. 2015 Jul;39(7):957-67. (PMID: 25723109) Blood. 2007 Oct 1;110(7):2259-67. (PMID: 17519389) Blood. 2016 May 19;127(20):2375-90. (PMID: 26980727) Blood. 2018 Nov 15;132(20):2125-2133. (PMID: 30429156) Haematologica. 2023 May 01;108(5):1442-1446. (PMID: 36519329) Lancet Oncol. 2017 Dec;18(12):1590-1599. (PMID: 29074098) J Clin Oncol. 2010 Sep 1;28(25):3987-93. (PMID: 20679620) Cancer Sci. 2020 Dec;111(12):4540-4547. (PMID: 33010107) Curr Probl Cancer. 2021 Aug;45(4):100768. (PMID: 34244015) J Thorac Dis. 2015 May;7(5):908-11. (PMID: 26101648) J Clin Oncol. 2023 Apr 10;41(11):2043-2053. (PMID: 36534942) |
| فهرسة مساهمة: | Keywords: ALK-positive NSCLC; Anaplastic large cell lymphoma; Inflammatory myofibroblastic tumors |
| تواريخ الأحداث: | Date Created: 20240427 Latest Revision: 20240622 |
| رمز التحديث: | 20240622 |
| مُعرف محوري في PubMed: | PMC11187053 |
| DOI: | 10.1007/s40487-024-00275-6 |
| PMID: | 38676786 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 2366-1089 |
|---|---|
| DOI: | 10.1007/s40487-024-00275-6 |